- Home
- RCS vs SLGL Comparison
RCS vs SLGL Comparison
Compare RCS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | SLGL |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.0M | 254.1M |
| IPO Year | 1994 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RCS | SLGL |
|---|---|---|
| Price | $5.18 | $69.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 119.5K | 57.5K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.09 | $23.15 |
| 52 Week High | $8.00 | $97.97 |
Technical Indicators
Market Signals| Indicator | RCS | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 40.03 |
| Support Level | $5.10 | $67.89 |
| Resistance Level | $5.67 | $81.18 |
| Average True Range (ATR) | 0.06 | 5.13 |
| MACD | -0.00 | -1.16 |
| Stochastic Oscillator | 7.14 | 17.86 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.